Cardiovascular Risk Biomarkers: What to Test – Medscape
- For decades, cholesterol levels have been the cornerstone of cardiovascular risk assessment.
- While cholesterol remains crucial, it doesn't tell the whole story.
- Researchers are investigating several promising biomarkers that go beyond traditional lipid panels.
Beyond Cholesterol: The Emerging Landscape of Cardiovascular Risk Biomarkers
Table of Contents
For decades, cholesterol levels have been the cornerstone of cardiovascular risk assessment. However, a growing body of research suggests that relying solely on customary markers like LDL-C provides an incomplete picture. As of October 9, 2025, the medical community is increasingly focused on a new generation of biomarkers that offer a more nuanced and perhaps predictive understanding of heart disease risk.
The Limitations of Traditional Risk Factors
While cholesterol remains crucial, it doesn’t tell the whole story. Many individuals with “normal” cholesterol levels still experience cardiovascular events, while others with elevated levels never develop heart disease. This highlights the need for additional tools to identify those truly at risk and tailor preventative strategies accordingly.
What are the New Biomarkers?
Researchers are investigating several promising biomarkers that go beyond traditional lipid panels. Thes include:
- Lipoprotein(a) [Lp(a)]: This genetically determined lipoprotein is now recognized as a significant independent risk factor for cardiovascular disease. Elevated Lp(a) levels contribute to plaque buildup and increase the risk of heart attack and stroke.
- High-Sensitivity C-Reactive Protein (hs-CRP): A marker of inflammation, hs-CRP levels can indicate underlying cardiovascular risk, even in individuals with normal cholesterol. Chronic inflammation plays a key role in the progress and progression of atherosclerosis.
- Apolipoprotein B (ApoB): ApoB measures the number of atherogenic particles – those capable of causing plaque buildup – in the blood. It’s considered a more accurate reflection of cardiovascular risk than LDL-C alone.
- Phospholipase A2 (PLA2): this enzyme is involved in inflammation and plaque instability. Elevated PLA2 activity is associated with an increased risk of cardiovascular events.
- Myeloperoxidase (MPO): Another marker of inflammation,MPO is released by white blood cells and contributes to oxidative stress and endothelial dysfunction.
Why are these Biomarkers Important?
These new biomarkers offer several advantages:
- Improved Risk Stratification: They help identify individuals at higher risk who might be missed by traditional assessments.
- Personalized Treatment: Understanding a patient’s biomarker profile allows for more targeted and effective preventative strategies.
- Early Detection: These markers can detect early signs of cardiovascular disease, potentially allowing for intervention before symptoms develop.
The Future of Cardiovascular Risk Assessment
The integration of these new biomarkers into routine clinical practice is still evolving. Ongoing research is focused on determining the optimal use of these tests, establishing clear clinical guidelines, and understanding how they interact with traditional risk factors. As of late 2025, the American Heart Association and the American College of Cardiology are actively evaluating the evidence to develop updated recommendations for cardiovascular risk assessment and management.
ultimately, the goal is to move towards a more complete and personalized approach to cardiovascular care, utilizing the full spectrum of available biomarkers to protect and improve heart health.